Inverse Androgenic Alopecia

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.

In this study, most male patients with androgenic alopecia who transitioned from oral to topical finasteride with minoxidil maintained good hair density.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

This review summarizes existing research on the use of finasteride for treating androgenetic alopecia in men, reporting its effectiveness at 1 mg/day and a strong safety profile, but presents no new findings.

This study reports that oral finasteride improved or stabilized hair loss in women with hyperandrogenism but not in postmenopausal women with female pattern hair loss.

This study found that finasteride can stop hair loss in 91% of men with androgenetic alopecia and promote visible hair growth in up to 66% of cases.

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.